Literature DB >> 19630826

Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy.

S Z Goldhaber1.   

Abstract

The optimal treatment strategy for acute pulmonary embolism relies upon a multidisciplinary team that rapidly assesses available data, performs additional testing if necessary, weighs treatment options, and recommends an appropriate therapeutic plan to the patient and family. Round-the-clock availability is imperative. Centers that specialize in pulmonary embolism management offer a wide range of therapeutic options. Hospitals with more limited facilities should establish pulmonary embolism patient referral and transfer contingency plans that can be activated at a moment's notice. Management options include anticoagulation alone, thrombolysis plus anticoagulation, insertion of an inferior vena caval filter, catheter embolectomy, or surgical embolectomy. The decision-making process requires accurate risk stratification, which is comprised of several crucial components: clinical evaluation that includes history and physical examination, biomarker measurement especially of troponin, as well as assessment of right ventricular size and function based upon chest CT scanning and echocardiography. The 'old school' approach of declaring a benign prognosis based solely upon the presence of normal systemic arterial pressure can delay advanced therapy until after the onset of irreversible cardiogenic shock. We have now formulated a more contemporary, comprehensive, and multifaceted strategy to prognosticate. Our 'new approach' uses advanced treatment strategies in addition to anticoagulation for those pulmonary embolism patients deemed to be at high risk for a poor outcome.

Entities:  

Mesh:

Year:  2009        PMID: 19630826     DOI: 10.1111/j.1538-7836.2009.03415.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Gastroesophageal reflux causing nutritional failure and vomiting in a teenager with cystic fibrosis and respiratory failure.

Authors:  Alexandra Higton; Sarah Collins; Diana Bilton
Journal:  J R Soc Med       Date:  2011-07       Impact factor: 5.344

2.  The efficacy of CT for detection of right ventricular dysfunction in acute pulmonary embolism, and comparison with cardiac biomarkers.

Authors:  Erdal İn; Ayşe Murat Aydın; Cengiz Özdemir; Sinem Nedime Sökücü; Mustafa Necati Dağlı
Journal:  Jpn J Radiol       Date:  2015-06-29       Impact factor: 2.374

3.  Surgical embolectomy for acute massive pulmonary embolism.

Authors:  Senol Yavuz; Faruk Toktas; Tugrul Goncu; Cuneyt Eris; Arif Gucu; Derih Ay; Burak Erdolu; Erhan Tenekecioglu; Kemal Karaagac; Hakan Vural; Ahmet Ozyazicioglu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 4.  Acute pulmonary embolism. Part 2: treatment.

Authors:  Josien van Es; Renée A Douma; Victor E A Gerdes; Pieter W Kamphuisen; Harry R Büller
Journal:  Nat Rev Cardiol       Date:  2010-09-14       Impact factor: 32.419

5.  Management of Pulmonary Embolism: 2010 State-of-the-Art Update.

Authors:  Teresa L Carman; Florian Gegaj
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04

6.  Approach to venous thromboembolism in the cancer patient.

Authors:  Andrea Piccioli; Paolo Prandoni
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

7.  Spiral computed tomographic pulmonary angiography in patients with acute pulmonary emboli and no pre-existing comorbidity: a prospective prognostic panel study.

Authors:  Reza Javadrashid; Maryam Mozayan; Mohammad Kazem Tarzamni; Mohammad Reza Ghaffari; Daniel F Fouladi
Journal:  Eur Radiol       Date:  2014-08-28       Impact factor: 5.315

8.  Automated axial right ventricle to left ventricle diameter ratio computation in computed tomography pulmonary angiography.

Authors:  Germán González; Daniel Jiménez-Carretero; Sara Rodríguez-López; Kanako K Kumamaru; Elizabeth George; Raúl San José Estépar; Frank J Rybicki; Maria J Ledesma-Carbayo
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.